We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

169 hedge funds and large institutions have $2.42B invested in Intercept Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 74 increasing their positions, 39 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 39

7% less funds holding

Funds holding: 181169 (-12)

20% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 49

21% less capital invested

Capital invested by funds: $3.05B → $2.42B (-$632M)

42% less call options, than puts

Call options by funds: $56.6M | Put options by funds: $96.8M

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
169
Holders Change
-12
Holders Change %
-6.63%
% of All Funds
4.51%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
39
Increased
74
Reduced
39
Closed
49
Calls
$56.6M
Puts
$96.8M
Net Calls
-$40.2M
Net Calls Change
+$29.3M
Name Holding Trade Value Shares
Change
Change in
Stake
BG
101
BlackRock Group
United Kingdom
$965K +$116K +626 +11%
VOYA Investment Management
102
VOYA Investment Management
Georgia
$956K -$30.8K -167 -3%
Wells Fargo
103
Wells Fargo
California
$921K -$581K -3,147 -35%
SG Americas Securities
104
SG Americas Securities
New York
$895K +$690K +3,736 +187%
NCCM
105
Nine Chapters Capital Management
New Jersey
$889K +$665K +3,600 +171%
B
106
Baird
Wisconsin
$888K +$1.05M +5,693 New
TD Asset Management
107
TD Asset Management
Ontario, Canada
$671K
Connor, Clark & Lunn Investment Management (CC&L)
108
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$671K +$794K +4,300 New
QF
109
QVT Financial
New York
$663K
SEI Investments
110
SEI Investments
Pennsylvania
$662K +$784K +4,243 New
BIM
111
BlackRock Investment Management
Delaware
$655K -$20.3K -110 -3%
Zurich Cantonal Bank
112
Zurich Cantonal Bank
Switzerland
$618K +$178K +964 +32%
UBS Group
113
UBS Group
Switzerland
$590K +$698K +3,778 New
AGM
114
Alpine Global Management
New York
$546K +$646K +3,500 New
M&T Bank
115
M&T Bank
New York
$526K -$762K -4,128 -55%
MAA
116
Managed Account Advisors
New Jersey
$519K +$215K +1,163 +54%
IRF
117
IBM Retirement Fund
New York
$461K +$51.9K +281 +10%
Citadel Advisors
118
Citadel Advisors
Florida
$451K -$1.87M -10,144 -78%
SCM
119
Stevens Capital Management
Pennsylvania
$411K -$2.62M -14,171 -84%
MIM
120
Marco Investment Management
Georgia
$406K +$148K +800 +44%
3NC
121
300 North Capital
California
$405K +$1.29K +7 +0.3%
Public Employees Retirement Association of Colorado
122
Public Employees Retirement Association of Colorado
Colorado
$380K -$1.11K -6 -0.2%
WS
123
Wedbush Securities
California
$346K +$409K +2,215 New
BIA
124
Biondo Investment Advisors
Pennsylvania
$343K
URS
125
Utah Retirement Systems
Utah
$343K

ICPT Hedge Fund Activity: Q4 2014 in Review

169 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2014, worth a combined $2.42B — down 21% from $3.05B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ICPT and 39 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 74 added.

The largest buyer was First Trust Advisors, adding an estimated $49.1M. The largest seller was Capital World Investors, cutting an estimated $43.2M.

  • 169 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2014, down from 181 in Q3 2014.
  • Funds reported $2.42B of Intercept Pharmaceuticals, Inc. stock for Q4 2014, down 21% quarter-over-quarter.
  • 39 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2014 and 49 closed out, a net change of -10 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2014 was First Trust Advisors, an estimated $49.1M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2014 was Capital World Investors, an estimated $43.2M sold.

Based on aggregated 13F filings for Q4 2014.